Sucraid Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The sucraid market research report is one of a series of new reports that provides sucraid market statistics, including sucraid industry global market size, regional shares, competitors with a sucraid market share, detailed sucraid market segments, market trends and opportunities, and any further data you may need to thrive in the sucraid industry. This sucraid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to telemedicine growth, supportive patient assistance programs, collaborations and partnerships, policy changes favoring rare diseases and focused clinical trials. Major trends in the forecast period include growth in recombinant enzyme production, advancements in oral biologic, expansion of synthetic biology, gene therapy integration, and development of biobetters.

The growth of the sucraid market is anticipated to be driven by the rising prevalence of rare genetic disorders. These conditions, caused by mutations or changes in an individual’s DNA, occur infrequently within the general population. The increasing recognition of genetic disorders can be attributed to advancements in genetic testing, improved detection methods, environmental factors, and certain lifestyle influences that may contribute to DNA mutations. Sucraid plays a critical role by providing enzyme replacement therapy to individuals with congenital sucrase-isomaltase deficiency (CSID), a rare genetic disorder. This therapy helps people digest sucrose and maltose, which are typically indigestible due to a deficiency in the sucrase-isomaltase enzyme. A report from the Cystic Fibrosis Trust in September 2023 highlighted that the number of people in the UK registered with cystic fibrosis surpassed 11,000 in 2022, marking a 5% increase from the previous year. This surge in the number of genetic disorder cases is expected to fuel the demand for sucraid.

The factor contributing to the expansion of the sucraid market is the increase in healthcare expenditure. Healthcare expenditure refers to the total spending on healthcare services and products over a defined period, often measured annually. Rising healthcare costs are driven by factors such as an aging population, the growing prevalence of chronic diseases, technological advancements in medicine, the increasing price of pharmaceuticals, and broader access to healthcare services. Sucraid, as an effective enzyme replacement therapy for CSID, helps reduce overall healthcare spending by preventing costly hospitalizations, diagnostic procedures, and complications arising from untreated digestive disorders. For instance, a report from the Centers for Medicare & Medicaid Services in December 2023 revealed that U.S. healthcare spending increased by 4.1% in 2022, reaching a total of $4.5 trillion, a faster growth rate compared to 3.2% in 2021. As healthcare spending continues to rise, the sucraid market is poised for growth.

The sucraid market is also experiencing growth due to regulatory approvals that expand treatment options and improve access. These approvals, granted by government or regulatory bodies, allow a drug, medical device, or treatment to be marketed for public use. In September 2023, QOL Medical LLC received approval from the U.S. Food and Drug Administration (FDA) for Sucraid (sacrosidase) in single-use containers, specifically designed for patients weighing over 33 pounds (15 kg). This approval addresses previous supply shortages and improves accessibility by providing a dosage form that remains stable at room temperature for up to three days. Such regulatory advancements not only restore the supply of sucraid but also emphasize the importance of innovation in delivering treatments for rare diseases.

The key company operating in the sucraid market is QOL Medical LLC.

North America was the largest region in the sucraid market in 2024. The regions covered in sucraid report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sucraid market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Sucraid is a prescription medication that contains sacrosidase, an enzyme that aids in the breakdown of sucrose (table sugar) into glucose and fructose. It is primarily used to treat congenital sucrase-isomaltase deficiency (CSID), a rare genetic disorder that impairs the body's ability to digest sucrose and other sugars.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for Sucraid include congenital sucrase-isomaltase deficiency (CSID), chronic diarrhea associated with CSID, and gastrointestinal symptoms that may suggest CSID. It is distributed through hospitals and pharmacies, serving a range of end users, including both pediatric and adult patients.

The sucraid market consists of sales of sucraid enzyme supplements, syrups and tablets, and pharmaceuticals for digestive health. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.